WO2000059940A3 - Gene et proteine lies au facteur de croissance d'origine plaquettaire - Google Patents

Gene et proteine lies au facteur de croissance d'origine plaquettaire Download PDF

Info

Publication number
WO2000059940A3
WO2000059940A3 PCT/US2000/006427 US0006427W WO0059940A3 WO 2000059940 A3 WO2000059940 A3 WO 2000059940A3 US 0006427 W US0006427 W US 0006427W WO 0059940 A3 WO0059940 A3 WO 0059940A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
platelet
growth factor
derived growth
related gene
Prior art date
Application number
PCT/US2000/006427
Other languages
English (en)
Other versions
WO2000059940A2 (fr
Inventor
Lisa Janine Hammond
Songqing Na
Original Assignee
Lilly Co Eli
Lisa Janine Hammond
Songqing Na
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Lisa Janine Hammond, Songqing Na filed Critical Lilly Co Eli
Priority to AU40085/00A priority Critical patent/AU4008500A/en
Publication of WO2000059940A2 publication Critical patent/WO2000059940A2/fr
Publication of WO2000059940A3 publication Critical patent/WO2000059940A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention, qui porte sur des méthodes visant à favoriser la cicatrisation ainsi que sur des méthodes visant à stimuler la régénération tissulaire, a trait également à des méthodes permettant de prévenir ou de traiter l'athérosclérose chez un patient. Ces méthodes consistent à administrer à ce patient une quantité efficace du point de vue thérapeutique de la protéine LP 8 liée au facteur de croissance d'origine plaquettaire (PDGF) ou de son antagoniste.
PCT/US2000/006427 1999-04-06 2000-03-24 Gene et proteine lies au facteur de croissance d'origine plaquettaire WO2000059940A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU40085/00A AU4008500A (en) 1999-04-06 2000-03-24 Platelet-derived growth factor related gene and protein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12791399P 1999-04-06 1999-04-06
US60/127,913 1999-04-06

Publications (2)

Publication Number Publication Date
WO2000059940A2 WO2000059940A2 (fr) 2000-10-12
WO2000059940A3 true WO2000059940A3 (fr) 2001-01-25

Family

ID=22432606

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/006427 WO2000059940A2 (fr) 1999-04-06 2000-03-24 Gene et proteine lies au facteur de croissance d'origine plaquettaire

Country Status (2)

Country Link
AU (1) AU4008500A (fr)
WO (1) WO2000059940A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2322792C (fr) 1998-03-17 2010-09-14 Genentech, Inc. Polypeptides homologues de vegf et bmp1
US6432673B1 (en) 1998-12-07 2002-08-13 Zymogenetics, Inc. Growth factor homolog ZVEGF3
US6630142B2 (en) 1999-05-03 2003-10-07 Zymogenetics, Inc. Method of treating fibroproliferative disorders
US6893637B1 (en) 1999-10-21 2005-05-17 Zymogenetics, Inc. Method of treating fibrosis
WO2001032197A2 (fr) * 1999-11-02 2001-05-10 Eli Lilly And Company Methodes d'utilisation de lp8, une proteine liee au pdgf, afin de traiter les troubles musculosquelettiques
US20040086507A1 (en) * 2000-10-19 2004-05-06 Kenya Shitara Antibody inhibiting vplf activity
ES2272573T3 (es) 2000-10-30 2007-05-01 Zymogenetics, Inc. Composiciones y metodos para mejorar la funcion renal.
CA2439612A1 (fr) * 2001-03-09 2002-09-19 Janssen Pharmaceutica N.V. Modulation de la proliferation des cellules des muscles lisses

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999037671A1 (fr) * 1998-01-27 1999-07-29 Eli Lilly And Company Gene et proteine associes au facteur de croissance des cellules endotheliales vasculaires
WO1999046281A2 (fr) * 1998-03-10 1999-09-16 Genentech, Inc. Nouveaux polypeptides et acides nucleiques les codant
WO1999047677A2 (fr) * 1998-03-17 1999-09-23 Genentech, Inc. Polypeptides homologues de vegf et bmp1
WO2000004183A1 (fr) * 1998-07-15 2000-01-27 Human Genome Sciences, Inc. Proteine morphogenetique osseuse
WO2000018212A2 (fr) * 1998-09-30 2000-04-06 Ludwig Institute For Cancer Research Facteur de croissance c derive des plaquettes, adn le codant et ses utilisations
WO2000034474A2 (fr) * 1998-12-07 2000-06-15 Zymogenetics, Inc. Zvegf3 homologue du facteur de croissance

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999037671A1 (fr) * 1998-01-27 1999-07-29 Eli Lilly And Company Gene et proteine associes au facteur de croissance des cellules endotheliales vasculaires
WO1999046281A2 (fr) * 1998-03-10 1999-09-16 Genentech, Inc. Nouveaux polypeptides et acides nucleiques les codant
WO1999047677A2 (fr) * 1998-03-17 1999-09-23 Genentech, Inc. Polypeptides homologues de vegf et bmp1
WO2000004183A1 (fr) * 1998-07-15 2000-01-27 Human Genome Sciences, Inc. Proteine morphogenetique osseuse
WO2000018212A2 (fr) * 1998-09-30 2000-04-06 Ludwig Institute For Cancer Research Facteur de croissance c derive des plaquettes, adn le codant et ses utilisations
WO2000034474A2 (fr) * 1998-12-07 2000-06-15 Zymogenetics, Inc. Zvegf3 homologue du facteur de croissance

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DATABASE GENEMBL 23 July 2000 (2000-07-23), HAMADA ET AL.: "Homo sapiens hSCDGF mRNA for spinal cord-derived growth factor, complete cds", XP002150978 *
DATABASE GENEMBL 31 October 1997 (1997-10-31), STRAUSBERG,R.: "nq75h03.s1 NCI_CGAP_Pr22 Homo sapiens cDNA clone IMAGE:1158197 3' mRNA sequence", XP002150975 *
DATABASE GENEMBL 6 July 2000 (2000-07-06), LI ET AL.: "Homo sapiens platelet-derived growth factor C mRNA, complete cds.", XP002150977 *
DATABASE GENEMBL 6 October 1999 (1999-10-06), TSAI ET AL.: "Homo sapiens secretory growth factor-like protein fallotein mRNA, complete cds.", XP002150976 *
DATABASE SWISSPROT 1 June 1998 (1998-06-01), REYNOLDS ET A.: "Bone morphogenic protein 1 from Gallus gallus (chicken)", XP002150974 *
HAMADA TSUYOSHI ET AL: "A novel gene derived from developing spinal cords, SCDGF, is a unique member of the PDGF/VEGF family.", FEBS LETTERS, vol. 475, no. 2, 2000, pages 97 - 102, XP000952876, ISSN: 0014-5793 *
LI XURI ET AL: "PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor.", NATURE CELL BIOLOGY, vol. 2, no. 5, May 2000 (2000-05-01), pages 302 - 309, XP000956444, ISSN: 1465-7392 *
TSAI YUAN-JANG ET AL: "Identification of a novel platelet-derived growth factor-like gene fallotein in the human reproductive tract.", BIOLOGY OF REPRODUCTION, vol. 60, no. SUPPL. 1, July 1999 (1999-07-01), Thirty-Second Annual Meeting of the Society for the Study of Reproduction;Pullman, Washington, USA; July 31-August 3, 1999, pages 242, XP000956454, ISSN: 0006-3363 *

Also Published As

Publication number Publication date
WO2000059940A2 (fr) 2000-10-12
AU4008500A (en) 2000-10-23

Similar Documents

Publication Publication Date Title
WO2002058684A3 (fr) Combinaisons de medicaments (par exemple de chlorpromazine et de pentamidine) pour le traitement de troubles neoplasiques
EP1426375A3 (fr) Dérivés analgétiques de spiroindole
WO2001078698A3 (fr) Utilisation des antagonistes du ngf dans la prevention et le traitement de la douleur viscerale chronique
UA56989C2 (uk) ФІЗІОЛОГІЧНО АКТИВНИЙ ПЕГ-КОН'ЮГАТ <font face="Symbol">a</font>-ІНТЕРФЕРОНУ, СПОСІБ ЙОГО ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЙОГО ОСНОВІ ТА СПОСІБ ЛІКУВАННЯ АБО ПРОФІЛАКТИКИ ІМУНОМОДУЛЯТОРНИХ ЗАХВОРЮВАНЬ
AU1227302A (en) System and method for optimizing drug therapy for the treatment of diseases
WO2004056307A3 (fr) Traitement de maladie par le biais d'inhibiteurs de peptides antimicrobiens
AU2001283518A1 (en) Method for controlling the pain from injections or minor surgical procedures andapparatus for use therewith
AU3725699A (en) Implantable tissue fastener and system for treating gastroesophageal reflux disease
WO2000064441A3 (fr) Medicament
AU7725700A (en) Implantable stimulation device for snoring treatment
WO2001000190A3 (fr) Utilisation de derives d'acide hyaluronique dans des preparations pharmaceutiques et des biomateriaux destines a la prevention et au traitement des cicatrices cutanees
AU2732001A (en) Apparatus and method of treatment of wounds, burns and immune system disorders
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
WO2002100390A3 (fr) Methode amelioree de traitement du syndrome des facteurs de risque de coronaropathie chez l'etre humain
AU7031500A (en) Therapeutic quinazoline compounds
AU6530600A (en) Use of neurotoxin for treating cardiac muscle disorders
WO2001043732A3 (fr) Utilisation d'antagonistes des recepteurs de retinoides dans le traitement de maladies cartilagineuses et osseuses
CA2154103A1 (fr) Traitement des maladies, traumatismes ou troubles de la membrane muqueuse, et pour le soulagement de la douleur
WO1999043344A3 (fr) Compositions proteiniques matricielles de cicatrisation
WO2001024783A3 (fr) Utilisation de (+)-tramadol, de o-demethyltramadol ou de (+)-o-demethyltramadol, de o-desmethyle-n-mono-desmethyl-tramadol ou de (+)o-desmethyl-n-mono-desmethyl-tramadol pour traiter l'incontinence urinaire
WO1999004772A3 (fr) Levobupivacine et son utilisation
WO2000059940A3 (fr) Gene et proteine lies au facteur de croissance d'origine plaquettaire
IL164822A0 (en) Growth factor delivery system for the healing of wounds and the prevention and disease
AU6539000A (en) Composition and method for treating disease by increasing activated alpha2 macroglobulin in the blood and extravascular tissue
AU3896900A (en) Treatment of pain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP